

5-Minute Journal Club: Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events of special interest is observed with datopotamab deruxtecan (Dato-DXd)?
  - a. Oral mucositis/stomatitis
  - b. Interstitial lung disease
  - c. Ocular surface events
  - d. All of the above**
  - e. None of the above
2. In a pooled analysis of clinical trial data presented at the 2024 San Antonio Breast Cancer Symposium, how do Dato-DXd and sacituzumab govitecan compare in terms of progression-free survival (PFS)?
  - a. PFS is similar between the 2 agents**
  - b. PFS is significantly better with datopotamab deruxtecan
  - c. PFS is significantly better with sacituzumab govitecan
3. Which of the following is an appropriate cytopenia management measure for a patient who is about to receive sacituzumab govitecan?
  - a. Prophylactic growth factor
  - b. Growth factor when cytopenia arises
  - c. Both a and b**
  - d. Neither a nor b
4. Which TROP2-targeting antibody-drug conjugate is administered once every 3 weeks?
  - a. Dato-DXd**
  - b. Sacituzumab govitecan
  - c. Trastuzumab deruxtecan
5. Which of the following adverse events is more common with sacituzumab govitecan than with Dato-DXd?
  - a. Oral mucositis/stomatitis
  - b. Neutropenia**
  - c. Ocular surface events